Literature DB >> 10491369

Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women.

M Roest1, Y T van der Schouw, B de Valk, J J Marx, M J Tempelman, P G de Groot, J J Sixma, J D Banga.   

Abstract

Background-The genetic background of hereditary hemochromatosis (HH) is homozygosity for a cysteine-to-tyrosine transition at position 282 in the HFE gene. Heterozygosity for HH is associated with moderately increased iron levels and could be a risk factor for cardiovascular death. Methods and Results-We studied the relation between HH heterozygosity and cardiovascular death in a cohort study among 12 239 women 51 to 69 years of age residing in Utrecht, the Netherlands. Women were followed for 16 to 18 years (182 976 follow-up years). The allele prevalence of the HH gene in the reference group was 4.0 (95% CI 2.9 to 5.4). The mortality rate ratios for HH heterozygotes compared with wild types was 1.5 (95% CI 0.9 to 2.5) for myocardial infarction (n=242), 2.4 (95% CI 1.3 to 3. 5) for cerebrovascular disease (n=118), and 1.6 (95% CI 1.1 to 2.4) for total cardiovascular disease (n=530). The population-attributable risks of HH heterozygosity for myocardial infarction and cerebrovascular and total cardiovascular death were 3. 3%, 8.8%, and 4.0%, respectively. In addition, we found evidence for effect modification by hypertension and smoking. Conclusions-We found important evidence that inherited variation in iron metabolism is involved in cardiovascular death in postmenopausal women, especially in women already carrying classic risk factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491369     DOI: 10.1161/01.cir.100.12.1268

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

Review 1.  Genetics of atherosclerosis: the search for genes acting at the level of the vessel wall.

Authors:  V Villa-Colinayo; W Shi; J Araujo; A J Lusis
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

Review 2.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

3.  The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease.

Authors:  S Campbell; D K George; S D Robb; R Spooner; T A McDonagh; H J Dargie; P R Mills
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

4.  Heterozygosity for the haemochromatosis mutation HFE C282Y is not a risk factor for angina.

Authors:  G P Feeney; P A L Ashfield-Watt; M L Burr; F D J Dunstan; I F W McDowell; M Worwood
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

5.  Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.

Authors:  H Zheng; X Huang; Q Zhang; S D Katz
Journal:  Kidney Int       Date:  2006-02       Impact factor: 10.612

Review 6.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

Review 7.  A safe strategy for addition of vitamins and minerals to foods.

Authors:  S E Rasmussen; N L Andersen; L O Dragsted; J C Larsen
Journal:  Eur J Nutr       Date:  2005-10-12       Impact factor: 5.614

8.  HFE mutations in heart disease.

Authors:  Terence Dunn; Derek Blankenship; Nicole Beal; Richard Allen; Eliot Schechter; William Moore; Ghazala Perveen; June Eichner
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

9.  HFE gene mutations increase the risk of coronary heart disease in women.

Authors:  M Carolina Pardo Silva; Omer T Njajou; Behrooz Z Alizadeh; Albert Hofman; Jacqueline C M Witteman; Cornelia M van Duijn; A Cecile J W Janssens
Journal:  Eur J Epidemiol       Date:  2010-07-18       Impact factor: 8.082

10.  Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium.

Authors:  Santhi K Ganesh; Neil A Zakai; Frank J A van Rooij; Nicole Soranzo; Albert V Smith; Michael A Nalls; Ming-Huei Chen; Anna Kottgen; Nicole L Glazer; Abbas Dehghan; Brigitte Kuhnel; Thor Aspelund; Qiong Yang; Toshiko Tanaka; Andrew Jaffe; Joshua C M Bis; Germaine C Verwoert; Alexander Teumer; Caroline S Fox; Jack M Guralnik; Georg B Ehret; Kenneth Rice; Janine F Felix; Augusto Rendon; Gudny Eiriksdottir; Daniel Levy; Kushang V Patel; Eric Boerwinkle; Jerome I Rotter; Albert Hofman; Jennifer G Sambrook; Dena G Hernandez; Gang Zheng; Stefania Bandinelli; Andrew B Singleton; Josef Coresh; Thomas Lumley; André G Uitterlinden; Janine M Vangils; Lenore J Launer; L Adrienne Cupples; Ben A Oostra; Jaap-Jan Zwaginga; Willem H Ouwehand; Swee-Lay Thein; Christa Meisinger; Panos Deloukas; Matthias Nauck; Tim D Spector; Christian Gieger; Vilmundur Gudnason; Cornelia M van Duijn; Bruce M Psaty; Luigi Ferrucci; Aravinda Chakravarti; Andreas Greinacher; Christopher J O'Donnell; Jacqueline C M Witteman; Susan Furth; Mary Cushman; Tamara B Harris; Jing-Ping Lin
Journal:  Nat Genet       Date:  2009-10-11       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.